Tudor Investment Corp’s Gyre Therapeutics GYRE Stock Holding History

Tudor Investment Corp’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,932	Closed	-$67K	–	1157
2017 Q2	$67K	Buy	+1,932	New	+$69.4K	﹤0.01%	974

Other funds holding GYRE

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Tudor Investment Corp's GYRE Position: Q3 2017 in Review

Tudor Investment Corp sold out of Gyre Therapeutics (GYRE) in Q3 2017, closing a stake of 1,932 shares — an estimated $67K sold.

Tudor Investment Corp first reported a position in GYRE in Q2 2017 and held it in 1 quarter. The position peaked at $67K in Q2 2017. 19 funds tracked by Wall St. Rank hold GYRE as of Q3 2017.

Tudor Investment Corp reported no remaining Gyre Therapeutics position as of Q3 2017 after selling out during the quarter.
Tudor Investment Corp sold 1,932 Gyre Therapeutics shares in Q3 2017, an estimated $67K.
Tudor Investment Corp first reported a position in Gyre Therapeutics in Q2 2017 and held it in 1 quarter.
Tudor Investment Corp's Gyre Therapeutics position peaked at $67K in Q2 2017.
19 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2017.

Based on Tudor Investment Corp's 13F filing for Q3 2017, filed 14 Nov 2017.